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Abstract
Frequent activation of the AKT serine-threonine kinase in cancer confers resistance to therapy. AKT is activated by a multi-
step process involving phosphatidylinositide (PtdIns) phosphate-mediated recruitment of AKT and its upstream kinases,
including 3-Phosphoinositide-dependent kinase 1 (PDK1), to the inner surface of the cell membrane. PDK1 in the
appropriate context phosphorylates AKT at threonine 308 (T308) to activate AKT. Whether PtdIns(3,4,5)Ps (PtdInsP3) binding
and AKT membrane translocation mediate functions other than formation of a functional PDK1::AKT complex have not been
fully elucidated. We fused complementary fragments of intensely fluorescent protein (IFP) to AKT1 and PDK1 to induce a
stable complex to study the prerequisites of AKT1 phosphorylation and function. In the stabilized PDK1-IFPC::IFPN-AKT1
complex, AKT1 T308 phosphorylation was independent of PtdIns, as demonstrated by treatment with Phosphatidylinositol 3
Kinase (PI3K) inhibitors. Further when interaction with PtdIns and the cell membrane was prevented by creating PH-domain
mutants of AKT1 (R25A) and PDK1 (R474A), AKT1 phosphorylation on T308 was maintained in the PDK1-IFPC::IFPN-AKT1
complex. The PDK1-IFPC::IFPN-AKT1 complex was sufficient for phosphorylation of known AKT substrates, and conferred
resistance to inhibitors of PI3K (LY294002, PI103, GDC0941 and TGX286) but not inhibitors of the downstream TORC1
complex (rapamycin). Thus the locus of action of targeted therapeutics can be elucidated by the constitutively active AKT1
complex. Our data indicate that PtdIns and membrane localization are not required for AKT phosphorylation and activation,
but rather serve to induce a functional physical interaction between PDK1 and AKT. The PDK1-IFPC::IFPN-AKT1 complex
provides a cell-based platform to examine specificity of drugs targeting PI3K pathway components.
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Introduction
The serine/threonine kinase AKT (also known as protein kinase
B, PKB), comprising a group of 3 isoforms, AKT1, AKT2, and
AKT3, plays a central role in cell metabolism, survival, growth,
motility, and tumorigenesis [1,2]. AKT is frequently activated in
cancer by amplification of growth factor receptors (HER2/neu,
EGFR), activating mutations of intracellular kinases (PIK3CA),
amplification or mutation of AKT isoforms, and inactivation of
phosphatases (PTEN) [3]. The development of effective, non-toxic
inhibitors that target AKT activation is thus an active field of
investigation. AKT is activated by a cascade of events that is
initiatedbytherecruitmentofclassI PI3Kstothe cellmembrane,as
occurs following activation of transmembrane receptor tyrosine
kinases. Class IA PI3K phosphorylates PtdIns(4,5)P (PtdInsP2) to
form PtdIns(3,4,5)Ps (PtdInsP3) on the inner cell membrane, which
recruits proteins with pleckstrin homology (PH) domains including
AKT and PDK1 to the cell membrane. Upon recruitment to the
cell membrane AKT is phosphorylated at two critical residues,
T308 in the activation T loop, and S473 in the hydrophobic
domain, to fully activate its kinase activity. PDK1 [4] phosphory-
lates AKT at T308, and mTORC2 [5] as well as other potential
PDK2s phosphorylates AKT at S473. The phosphorylated, active
AKT then translocates from the cell membrane to other cell
compartments to phosphorylate its downstream substrates that
critically regulate many cellular processes [6]. Recent studies have
uncovered many details in each step of the activation process. AKT
has been shown to form complex with PDK1 in both resting and
stimulated cells[7,8]. A ‘‘PH-in’’ conformation of AKT prevents
PDK1 from phosphorylating AKT in resting cells. Association of
AKT and potentially PDK1 with PtdIns alters the PH-in
conformation allowing phosphorylation of AKT at T308[7,8].
Multiple scaffold proteins, including PAK and Freud-1, have also
been identified to facilitate AKT association with PDK1 promoting
AKT translocation and phosphorylation[9,10]. Ubiquitination has
also been shown to promote AKT translocation and activation[11].
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dependent process. However, many of the prerequisites to AKT
phosphorylationhave not been fully clarified, i.e., whether PtdInsP3
binding or membrane localization is indispensable for AKT
phosphorylation by PDK1. An improved understanding of this
requirement for AKT activation could help refine drug develop-
ment approaches targeting the activated AKT pathway.
We hypothesized that PtdInsP3 binding and membrane
localization is not required for AKT phosphorylation and
activation by PDK1 if the two proteins could be brought into
proximity as stable complex with proper conformation by
alternative mechanisms. Previously, we have used protein-
fragment complementation assays (PCA) to screen for protein-
protein interactions with AKT1 in intact cells [12]. In PCA, a
reporter protein such as a monomeric enzyme or a fluorescent
protein (GFP or a variant thereof, IFP will be used as an example
here) is rationally dissected into 2 fragments that do not
reconstitute spontaneously [13,14,15]. When each fragment of
IFP is fused to one of a pair of interacting protein partners, the
subsequent protein interaction places the IFP fragments in
proximity restoring IFP molecules and fluorescence. The recon-
stituted barrel structure of IFP is relatively stable [16] so PCA has
the potential to stabilize transient interactions, such as enzyme–
substrate interactions. We took advantage of the reconstitution of
IFP fragments to generate stable complexes of PDK1 and AKT1
in the absence of PI3K activity and membrane localization. The
results show that the physical association of PDK1 with AKT1
induced by reconstituted IFP is sufficient to produce T308
phosphorylation and activation of AKT1 independent of PI3K
activation or membrane localization. The constitutively activated
PDK1::AKT1 complex provides a cell-based platform to examine
drug specificities in the PI3K pathway. The results also
demonstrate that the activation of AKT1, and induction of
resistance to PI3K pathway inhibitors as well as paclitaxel, can be
achieved in the absence of membrane localization of AKT1.
Results and Discussion
AKT1 interaction with PDK1 is stabilized by reconstituted
IFP
To determine the effect of the interaction of AKT with PDK1
on AKT phosphorylation and activation, we employed PCA
technology to create a stable complex containing the two proteins.
IFP, a GFP derivative, also known as Venus [17], was used. An
IFP N-terminal portion of amino acid 1-158 (IFPN) and an IFP C-
terminal portion of amino acid 159-239 (IFPC) were synthesized
previously [15]. Neither IFP fragment is fluorescent by itself, nor
do they associate spontaneously [15,18]. IFPN was fused to the N-
terminus of AKT1, and IFPC to the C-terminus of PDK1 (Fig. 1A).
Following transfection into HeLa cells, PDK1-IFPC was readily
immunoprecipitated by anti-AKT antibody and detected with
anti-PDK1 antibody. In contrast, endogenous PDK1 was not
detected under these conditions suggesting that the endogenous
PDK1::AKT interaction was not stable to the immunoprecipita-
tion approach used in this study (Fig. 1B). The results confirmed
the physical interaction between PDK1-IFPC and IFPN-AKT1
and stabilization of the complex by the reconstituted IFP. The co-
expression of PDK1-IFPC and IFPN-AKT1 resulted in fluores-
cence (Fig. 1C), indicating that the interaction between AKT1 and
PDK1 brought the two IFP fragments into proximity and restored
IFP fluorescence, as observed previously [12]. We previously
showed that actinin 4 (ACTN4) is an interaction partner of AKT1.
Co-expression of IFPN-AKT1 and IFPC-ACTN4 resulted in
fluorescence. In contrast, cells with co-expression of IFPN-AKT1
with IFPC only or IFPC-ACTN4D310-911 (C terminal truncation
of ACTN4) were not fluorescent confirming lack of spontaneous
association of the IFP fragments [12]. The reconstitution of IFP
fluorescence, representing the formation of a stabilized PDK1-
IFPC::IFPN-AKT1 complex, allowed direct observation of the
subcellular localization of the complex. In serum-starved cells,
fluorescence was observed in the cytoplasm and the cell leading
edge (Fig. 1C). The majority of the fluorescence translocated to the
cell membrane upon serum stimulation for 10 minutes. Treatment
with the PI3K inhibitor LY294002 did not abrogate the formation
of the PDK1-IFPC::IFPN-AKT1 complex, as the cells retained
fluorescence. However, both basal- and serum-stimulated location
of the PDK1-IFPC::IFPN-AKT1 complex to the cell leading edge
and the membrane, respectively, were abrogated by LY294002
treatment (Fig. 1C). The localization dynamics of the complex is
consistent with that proposed for endogenous AKT and PDK1
[6,19]. Similar observations regarding PCA-stabilized protein
complex subcellular localization following PI3K inhibition have
also been previously reported [15]. Thus our results indicate that
the subcellular localization but not the formation of the PDK1-
IFPC::IFPN-AKT1 complex is dependent on PI3K activity.
Both endogenous PDK1 and AKT have been reported to
accumulate in the nucleus following treatment with Leptomycin B
(LMB) to inhibit nuclear export [20,21]. Accumulation of
fluorescence in the nucleus was observed in the presence of
LMB indicating that the PDK1-IFPC::IFPN-AKT1 complex,
similar to the endogenous proteins [6,21], can translocate into the
nucleus (Fig. 1D). LMB treatment did not affect the fluorescence
localization at the cell leading edge in serum-starved cells (data not
shown). The fluorescence at the cell leading edge was not
displayed in Figure 1D because the cell edges were out of focus
when the nuclei were in the focal plane. LMB dependent nuclear
localization also occurred in the presence of LY294002 (data not
shown). Taken together, fusing the complementary fragments of
IFP to PDK1 and AKT1 reconstituted IFP fluorescence and
facilitated the formation of a PDK1-IFPC::IFPN-AKT1 complex
with appropriate subcellular localization.
PI3K-independent AKT1 phosphorylation and activation
by PDK1
Since IFP reconstitution led to the stabilization of the PDK1-
IFPC::IFPN-AKT1 complex with appropriate subcellular localiza-
tion, we sought to determine whether such stable AKT1 association
with PDK1 was sufficient for AKT1 phosphorylation and
activation. In HeLa cells expressing IFPN-AKT1 only (Fig. 2A,
lane 6), the relative levels of IFPN-AKT1 phosphorylation at T308
and S473 (arrow head) were comparable to that of endogenous
AKT (arrows), indicating IFPN-AKT1 was phosphorylated simi-
larlytoendogenousAKT.Co-expressionwithPDK1-IFPC(Fig.2A,
lane 7) led to a substantial increase in IFPN-AKT1 phosphorylation
at both sites. Strikingly, while the phosphorylation of AKT in either
non-transfected or IFPN-AKT1 alone transfected cells was
completed abolished by treatment with LY294002 (Fig. 2A, lane
1 and lane 2), IFPN-AKT1 phosphorylation on T308 in cells co-
expressing PDK1-IFPC was resistant to LY294002 treatment
(Fig. 2A, lane 3), indicating that PDK1-IFPC phosphorylated
IFPN-AKT1 in the complex independent of PI3K activity. In these
cells, IFPN-AKT1 was also strongly phosphorylated at S473 in the
presence or absence of LY294002, though the phosphorylation was
partially inhibited by LY294002, indicating the complex formation
stabilized by the reconstituted IFP also promoted AKT1 S473
phosphorylation (Fig. 2A, lane 3 and lane 7). We demonstrated the
PI3K-independent IFPN-AKT1 phosphorylation at S473 in the
complex is still dependent on the mTOR-rictor complex
Hyperactive PDK1::AKT1 Complex
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Endogenous AKT phosphorylation remained sensitive to
LY294002 in cells co-expressing IFPN-AKT1 and PDK1-IFPC
indicative of efficient inhibition of PI3K. To confirm that the
phosphorylationof IFPN-AKT1 wasdependent on theformationof
the PDK1-IFPC::IFPN-AKT1 complex rather than simply due to
PDK1 overexpression, we compared IFPN-AKT1 phosphorylation
in the cells transiently transfected with PDK1-IFPC or PDK1-GFP.
Although the expression level of PDK1-GFP was much higher than
PDK1-IFPC, in the presence of LY294002, IFPN-AKT1 was only
phosphorylated when co-transfected with PDK1-IFPC (Fig. 2B,
lane 2). Thus, PDK1 overexpression without stabilization of the
interaction between PDK1 and AKT1 is not sufficient for PI3K-
independent AKT phosphorylation. The amount of both transfect-
ed AKT1 and PDK1, which was 3–6 fold and 4–8 fold greater than
endogenous AKT and PDK1 in HeLa cells, respectively (Fig. 2A
and Figure S2), was comparable to the levels found in other cancer
cells with amplification of AKT and PDK1 (Figure S3).
The known AKT substrate, GSK3, was phosphorylated at
comparable levels in cells expressing the complex with or without
LY294002 treatment (Fig. 2A, lane 3 and lane 7), indicating that
IFPN-AKT1 in the complex is active and able to efficiently
phosphorylate downstream substrates in the presence of LY294002.
PDK1 overexpression alone was not sufficient to induce GSK3
phosphorylation (Figure S2). S6 phosphorylation was markedly
inhibited by LY294002 treatment compatible with the expected
inhibition of mTORC1 by LY294002 (Fig. 2A). In the presence of
LY294002, the PDK1-IFPC::IFPN-AKT1 complex partially re-
stored S6 phosphorylation indicating that the complex promotes
mTORC1-dependent p70S6K activity (Fig. 2A). To examine the
effects of the PDK1-IFPC::IFPN-AKT1 complex on the ability of
AKT to phosphorylate multiple substrates, western blotting analysis
Figure 1. AKT1 interaction with PDK1 stabilized by the reconstituted IFP. (A) Schematic diagram showing the split IFP reconstitution
mediated by the interaction between AKT1 and PDK1. IFPN was fused to the N-terminus of AKT1. IFPC was fused to the C-terminus of PDK1. Neither
fusion protein was fluorescent. The interaction between AKT1 and PDK1 brings IFPN and IFPC in proximity and reconstitutes IFP fluorescence. The
reconstituted IFP stabilizes the PDK1-IFPC::IFPN-AKT1 complex. (B) Association of PDK1-IFPC with IFPN-AKT1. HeLa cells stably expressing the PDK1-
IFPC::IFPN-AKT1 complex were lysed in NP40 lysis buffer. Immunoprecipitation was performed with the indicated antibodies (top labels), followed by
western blotting with anti-PDK1 (upper blot) and anti-AKT (lower blot). Lane 1, IP with normal IgG. Lane 2, IP with anti-AKT1. Lane 3, blank. Lane 4,
total cell lysate. (C) Translocation of the PDK1-IFPC::IFPN-AKT1 complex upon PI3K signaling activation or inhibition. Cells stably expressing the PDK1-
IFPC::IFPN-AKT1 complex were serum starved for overnight then treated with LY294002 (20 mM) for 3 hours (image 2), 10% serum for 10 minutes
(image 3), and LY294002 (20 mM) for 3 hours and then 10% serum for 10 minutes (image 4). At least 100 cells were examined from different fields for
each sample with 100% of the examined cells in each sample showing the same fluorescence localization presented. (D) Accumulation of the PDK1-
IFPC::IFPN-AKT1 complex in nucleus with LMB treatment. HeLa cells stably expressing the PDK1-IFPC::IFPN-AKT1 complex were starved overnight and
then treated with LMB at 50 nM for 3 hours. Nuclei were stained with Hoechst 33342.
doi:10.1371/journal.pone.0009910.g001
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consensus motif in AKT substrates (Fig. 2C). The presence of the
PDK1-IFPC::IFPN-AKT1 complex correlated with marked phos-
phorylation of several protein species in the presence or absence of
LY294002 indicating the PDK1-IFPC::IFPN-AKT1 complex
phosphorylates multiple substrates independent of PtdInsP3
(Fig. 2C, arrow heads). However, some substrates were more
sensitive to the effects of LY294002 such as the low molecular
weight band in Figure 2C. Differential sensitivity of AKT substrates
to modification of AKT phosphorylation has been reported
previously [22] and may thus reflect the relative sensitivity of
S473 phosphorylation to LY294002 in cells expressing the PDK1-
IFPC::IFPN-AKT1 complex.
We further confirmed that AKT1 phosphorylation in the
PDK1-IFPC::IFPN-AKT1 complex was independent of PI3K
activity using the PI3K inhibitor, GDC0941. Similar to LY294002
treatment, AKT1 T308 phosphorylation and GSK3 phosphory-
lation were comparable with/without GDC0941 treatment.
AKT1 phosphorylation at S473 was partially resistant to
GDC0941 treatment. S6 phosphorylation was sensitive compatible
with GDC0941 also inhibiting mTORC1 activity at the
concentrations used (Figure S4).
The ability of the PH domains of AKT1and PDK1 tointeract
with membrane phosphatidylinositols is not required for
IFPN-AKT1 T308 phosphorylation in the complex
The PH domains of AKT and PDK1 mediate membrane
recruitment through binding to phosphatidylinositol lipids [6,19].
To confirm that phosphorylation of IFPN-AKT1 by PDK1-IFPC
Figure 2. PI3K-independent AKT phosphorylation and activation. (A) AKT phosphorylation and activation in the PDK1-IFPC::IFPN-AKT1
complex. Four stable cell lines, parental HeLa, cells expressing IFPN-AKT1 only, cells co-expressing IFPN-AKT1 and PDK1-IFPC, and cells co-expressing
IFPN-AKT1 and IFPC-ACTN4, were serum starved for overnight then treated or not treated with LY294002 (20 mM) for 3 hours. Cells were lysed in RIPA
buffer supplied with protease inhibitors and phosphatase inhibitors. Lysates (50 mg/lane) were resolved in 10% SDS PAGE. Antibodies for each blot
were listed to the left of the blots. b-actin immunoblotting shows equivalent loading. The arrow head designates IFPN-AKT1. The arrow designates
endogenous AKT. Scanning densitometric values of western blots were obtained using the NIH image 1.63.1 software. IFPN-AKT1 phosphorylation
was normalized to total IFPN-AKT1. GSK3 (S21/9) and S6 (S235/236) phosphorylation was normalized to b-actin. Data were presented as relative
conversion to values of the sample in lane 7. (B) The reconstituted IFP is indispensable for the PI3K-independent IFPN-AKT1 phosphorylation. HeLa
cells stably expressing IFPN-AKT1 were transiently transfected with PDK1-IFPC or PDK1-GFP. Cells were serum starved for overnight and then treated
with LY294002 (20 mM) for 3 hours. The arrow head designates IFPN-AKT1. The arrow designates endogenous AKT. (C) Phosphorylation of AKT
substrates by the PDK1-IFPC::IFPN-AKT1 complex. Parental HeLa, cells stably expressing IFPN-AKT1 only, and cells stably co-expressing IFPN-AKT1 and
PDK1-IFPC were serum starved for overnight then treated or not treated with LY294002 (20 mM) for 3 hours. Anti-phospho-AKT substrate antibody
was used to detect the phosphorylation of AKT substrates. Two arrow heads designate the protein species with elevated phosphorylation level in the
LY294002 treated cells stably expressing the PDK1-IFPC::IFPN-AKT1 complex.
doi:10.1371/journal.pone.0009910.g002
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localization, we created IFPN-AKT1(R25A) and PDK1(R474A)-
IFPC PH domain mutants which abrogate membrane localization
of each protein [19,23]. HeLa cells transiently expressing the wild
type PDK1-IFPC::IFPN-AKT1 complex (Fig. 3A) displayed the
same localization pattern as was seen with stable transfection of the
complex in HeLa cells (Fig. 1C) with serum starvation, serum
stimulation, and treatment with LY294002. Co-transfection of
IFPN-AKT1(R25A) and PDK1(R474A)-IFPC, with the other
mutated protein or with the wild-type version of the complemen-
tary protein, also resulted in fluorescence, indicating that these
mutant proteins formed a stabilized complex in living cells
(Fig. 3A). The fluorescent complexes containing either mutant
protein, however, failed to demonstrate localization at the cell
leading edge or serum-stimulated membrane translocation. Thus,
the integrity of PH domains in both AKT1 and PDK1 is required
for the membrane localization of the PDK1-IFPC::IFPN-AKT1
complex.
IFPN-AKT1(R25A) was phosphorylated at T308 in the
PDK1(R474A)-IFPC::IFPN-AKT1(R25A) complex to an extent
comparable to wild type IFPN-AKT1 in the complex, though with
a slight decrease, in starved cells with or without LY294002
treatment (Fig. 3B, compare lane 3 with lane 2, or lane 6 with lane
5; relative phosphorylation levels shown in the densitometry bar
graphs), further confirming that AKT can be phosphorylated in
the complex without membrane localization of AKT and PDK1.
In contrast, IFPN-AKT1(R25A) phosphorylation at S473 was
reduced comparing with wild type IFPN-AKT1 under starvation
conditions with or without LY294002 (Fig. 3B, compare lane 3
with lane 2, or lane 6 with lane 5), indicating that the S473
phosphorylation in the complex demonstrates greater PI3K and
membrane localization dependence than the T308 phosphoryla-
tion. As expected, the phosphorylation level of IFPN-AK-
T1(R25A) at T308 and S473 was not increased by serum
stimulation (Fig. 3B, compare lane 9 with lane 6), which is
consistent with previous work [23].
We further confirmed the PH domain independent phosphor-
ylation of AKT1 in the complex by treatment with a selective
AKT PH domain inhibitor, Akti-1/2. (Bilodeau, 2008). As
expected, AKT1 T308 phosphorylation and GSK3 phosphoryla-
tion were comparable in the presence or absence of Akti-1/2.
AKT1 phosphorylation at S473 was partially resistant to the
treatment. S6 phosphorylation was unaltered in the presence or
absence of Akti-1/2 indicating that the inhibitor has no off target
effect on mTORC1 and p70S6K, and the PDK1-IFPC::IFPN-
AKT1 complex is responsible for mTORC1-dependent p70S6K
activation in the presence of Akti-1/2 (Figure S5).
The PDK1-IFPC::IFPN-AKT1 complex provides a cell-based
platform to examine specificity of drugs targeting PI3K
pathway components
The PDK1-IFPC::IFPN-AKT1 complex remained active and
did not localize to the membrane in the presence of LY294002,
which offered the opportunity to evaluate localization and activity
dependent functions of AKT1 and PDK1 separately. Further, the
constitutive activation of the PDK1-IFPC::IFPN-AKT1 complex
in the presence of LY294002 allowed us to access its specific
function in the context of PI3K inhibition, which abrogates
endogenous signaling. We thus determined whether the PDK1-
IFPC::IFPN-AKT1 complex could promote cell viability, a major
cellular function of the endogenous PDK1 and AKT, when
particular PI3K pathway components were inhibited. The
expression of the PDK1-IFPC::IFPN-AKT1 complex, but not
IFPN-AKT1 either alone or with IFPC-ACTN4, promoted cell
viability in the presence of PI3K inhibitors, LY294002 and PI103,
indicating the hyperactive PDK1-IFPC::IFPN-AKT1 was suffi-
cient to increase cell viability in the absence of PI3K signaling
(Fig. 4A). The effects were dependent on formation of the PDK1-
IFPC::IFPN-AKT1 complex as IFPN-AKT1:IFPC-ACTN4 or
Figure 3. The effects of AKT and PDK1 PH domain mutations
on PI3K-independent AKT phosphorylation. (A) PH domain
mutations abolish membrane translocation of the PCA-stabilized
protein complexes. HeLa cells were transiently transfected to co-
express a pair of fusion proteins shown above each column of images.
Cells were starved overnight (upper panel) and treated with serum for
10 minutes (middle panel) or LY294002 for 3 hours (lower panel). At
least 100 cells were examined from different fields for each sample with
above 95% of the examined cells in each sample showing the same
fluorescence localization presented. (B) IFPN-AKT1 phosphorylation in
the complex is independent of PtdInsP3 binding of both AKT and PDK1.
U2OS cells were used because of higher transfection efficiency than
HeLa. Cells were transiently co-transfected with IFPN-AKT1 and PDK1-
IFPC (lane 2, 5, and 8) or with IFPN-AKT1(R25A) and PDK1(R474A)-IFPC
(lane 3, 6, and 9). Cells were serum starved for overnight and then
treated with LY294002 (20 mM) or serum (10%) for 3 hours. Parental
U2OS was included as controls (lane 1, 4, and 7). Scanning
densitometric values of western blots were obtained using the NIH
image 1.63.1 software. Phosphorylation of IFPN fusions was normalized
to total IFPN fusion proteins. Data were presented as relative
conversion to values of the sample in lane 5. The arrow head
designates IFPN-AKT1. The arrow designates endogenous AKT.
doi:10.1371/journal.pone.0009910.g003
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presence of LY294002 or PI103 (Fig. 4A and D). The complex
only partially bypassed the effects of LY294002 or PI103. As both
LY294002 and PI103 inhibit other targets including mTOR, this
could indicate off target effects of these compounds such as
inhibition of mTOR-p70S6K in cell viability[24]. We also tested
two other PI3K inhibitors that are proposed to have less activity
on mTOR, GDC0941 and TGX286 (Fig. 4B). GDC0941 is a pan
PI3K inhibitor with weak inhibition on mTORC1[25]. The
PDK1-IFPC::IFPN-AKT1 complex promotes cell viability in the
presence of GDC0941 (Fig. 4B). Further, while GDC0941 and
LY294002 suppressed cell viability to a similar degree in control
cells, i.e. GDC0941 at 5 mM and LY294002 at 20 mM, the PDK1-
IFPC::IFPN-AKT1 complex restored cell viability to a signifi-
cantly higher level when treated with GDC0941 than treated with
LY294002 or PI103 (Fig. 4A and B), consistent with GDC0941
has less off target activity than LY294002 and PI103. TGX286 is a
selective inhibitor for PI3Kb/d without inhibition on mTOR
complexes (Knight 2006). The PDK1-IFPC::IFPN-AKT1 com-
plex completely restores cell viability with TGX286 treatment
(Fig. 4B), indicating the drug has no or little off target effects other
than inhibiting PI3K, which could be completely bypassed by the
PDK1-IFPC::IFPN-AKT1 complex. The data also suggest that
AKT1 is the primary mediator downstream of the drug targets,
PI3Kb/d, in promoting cell viability. Therefore, this approach
could potentially distinguish between on and off target activity of
PI3K inhibitors in functional outcomes. It is important to note that
the current studies were performed with AKT1, thus effects of
AKT2 and AKT3 would be inhibited by LY294002, PI103, or
GDC0941. So the PDK1-IFPC::IFPN-AKT1 complex provides
the opportunity to explore the effects of selective activation of
AKT1 in the absence of activation of AKT2 or AKT3.
The PDK1-IFPC::IFPN-AKT1 complex also reduced sensitiv-
ity to the selective AKT1 and AKT2 PH domain inhibitor, Akti-
1/2 [26,27] (Fig. 4C), confirming the activation of IFPN-AKT1 in
the complex is PH domain independent as shown in Figure 3B and
Figure S5. Once again there was only partial protection
compatible with off target effects of the inhibitor or effects on
AKT2. In contrast, the PDK1-IFPC::IFPN-AKT1 did not render
cells resistant to rapamycin, an inhibitor of mTOR, which is
downstream of AKT (Fig. 4C), confirming that mTORC1 is the
primary mediator downstream of AKT1 in promoting cell
viability. Rapamycin reduced the cell viability by ,30% at the
concentration of 10 nM (Fig. 4C). Higher concentration of
rapamycin (up to 1 mM) did not further reduce the cell viability
(Figure S6), compatible with 10 nM of rapamycin completely
inhibiting mTORC1 and higher concentration of rapamycin not
exhibiting additional off target effects on cell viability. The data
indicated that complete mTORC1 inhibition would induce an
approximately ,30% reduction in cell viability in these cells.
PI103 is a dual PI3K and mTORC1 inhibitor[24]. PI103
treatment at 1 mM reduced cell viability by ,30% in cells
expressing the PDK1-IFPC::IFPN-AKT1 complex (Fig. 4A),
which is consistent with the ,30% reduction in cell viability with
rapamycin treatment (Fig. 4C). In contrast, PI103 treatment at
1 mM reduced cell viability by ,60% in control cells (Fig. 4A),
suggesting in addition to the ,30% reduction induced by
mTORC1 inhibition, there was another ,30% reduction induced
by PI3K inhibition in control cells. The data suggest that the
PDK1-IFPC::IFPN-AKT1 complex, completely bypassed the
,30% reduction in viability induced by PI3K inhibition but
retained sensitivity to the ,30% reduction in viability induced by
mTORC1 inhibition. The data also imply that the effects of PI3K
inhibition and mTORC1inhibition are additive. Further, the data
suggest that PI103 has no or little effects other than inhibiting
PI3K and mTORC1 on cell viability, because PI3K inhibition was
completely bypassed by the PDK1-IFPC::IFPN-AKT1 complex.
LY294002 treatment at 20 mM exhibited similar inhibition
pattern, ,60% of reduction in control cells and ,30% of
reduction in cells expressing the PDK1-IFPC::IFPN-AKT1
complex. However, LY294002 and PI103 at higher concentrations
may exhibit additional off target effects. Although PI103 and
Figure 4. The effects of the PDK1-IFPC::IFPN-AKT1 complex on cell viability. Five cell lines were used in cell viability assays including
parental HeLa and four stable HeLa cell lines expressing IFPN-AKT1 alone, co-expressing IFPN-AKT1 and PDK1-IFPC, co-expressing IFPN-AKT1 and
IFPC-ACTN4, or expressing PDK1-GFP alone, respectively. Cells were plated in 96-well plates in complete medium at 3000 cells/well. After 18–
24 hours, cells were treated with drugs at different concentrations for 24 hours. Cell viability was measured by CellTiter Blue Cell Viability assay
according to manufacturer’s instructions. Data presented as survival rates normalized to non-treatment controls, respectively. Error bars were the
standard deviations of triplicates of each treatment. Cell viability in each treatment was also plotted against the logarithm of drug concentration by
fitting to the 3-parameter log(inhibitor) vs. response curve in GraphPad Prism version 5.0. IC50 was calculated by interpolating corresponding cell
viability curve. (A) The PDK1-IFPC::IFPN-AKT1 complex promotes cell viability with LY294002 or PI103 treatment. (B) The PDK1-IFPC::IFPN-AKT1
complex promotes cell viability with GDC0941 or TGX286 treatment. (C) The PDK1-IFPC::IFPN-AKT1 complex promotes cell viability with Akti-1/2 but
has no effect on cell viability with rapamycin treatment. (D) The PDK1-IFPC::IFPN-AKT1 complex promotes cell viability with paclitaxel treatment and
combined treatment with LY294002 and paclitaxel.
doi:10.1371/journal.pone.0009910.g004
Table 1. Drug sensitivity in cells expressing the PDK1-IFPC::IFPN-AKT1 complex.
No. Drugs Known targets Drug sensitivity in cells expressing the PDK1-IFPC::IFPN-AKT1 complex*
1 LY294002 Pan PI3K, mTORC1 +
2 PI103 Pan PI3K, mTORC1 +
3 GDC0941 Pan PI3K, mTORC1 ++
4 TGX286 PI3Kb/d +++
5 Akti-1/2 AKT1, AKT2 ++
6 Rapamycin mTORC1 2
*‘‘+++’’ indicates completely resistant. ‘‘2’’ indicates completely sensitive.
doi:10.1371/journal.pone.0009910.t001
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DNA-PK, ATR[24], the data suggest that the inhibition of PI3K
and mTORC1 primarily contributes to cell viability reduction.
Six drugs targeting the components in the PI3K-AKT-mTor
signaling were tested (Table 1). The PDK1-IFPC::IFPN-AKT1
complex was resistant to inhibition of PI3K upstream of AKT, as
well as inhibition of the AKT PH domain, while retaining
sensitivity to inhibitors that target the pathway downstream of
AKT. The PDK1-IFPC::IFPN-AKT1 complex was only partially
resistant to LY294002 and PI103 likely due to the ability of the
two drugs to effectively inhibit mTORC1 as well as PI3K. The
PDK1-IFPC::IFPN-AKT1 complex exhibited partial resistance to
GDC0941 likely because GDC0941 inhibits mTORC1 though
weaker than LY294002 and PI103. The PDK1-IFPC::IFPN-
AKT1 complex exhibited complete resistance to TGX286, a
selective PI3Kb/d inhibitor without inhibition on mTORC1.
The PDK1-IFPC::IFPN-AKT1 complex could also be used to
examine if AKT1 activation is responsible for a resistance to drugs
targeting non PI3K pathway mediated events. As shown in
Figure 4D, the PDK1-IFPC::IFPN-AKT1 complex mediated
partial resistance to paclitaxel and to combined treatment with
LY294002 and paclitaxel (Fig. 4D and Figure S6), indicating that
AKT1 contributes to drug resistance to paclitaxel in the cells
examined. Cells treated with both LY294002 and paclitaxel
exhibited lower cell viability than treated with the individual drug
indicating paclitaxel inhibits cell viability, at least partially,
independent of PI3K-AKT-mTor signaling.
Our results suggest that mechanisms independent of membrane
PtdIns could enable AKT phosphorylation by PDK1. For
example, any protein or other molecules that enhances
PDK1::AKT interaction or alters conformation of the complex
could be sufficient to promote AKT phosphorylation and
activation. Recently, p21-activated protein kinase 1 (PAK1) was
shown to serve as a scaffold to promote AKT interaction with
PDK1 and subsequently AKT phosphorylation [9], which is
consistent with this contention. Indeed a PDK1 PH domain
mutant (K465E) which lacks PtdInsP3 binding, retained an ability
to phosphorylate AKT in knock-in mice, albeit at a reduced level
[28]. Furthermore, stress-induced phosphorylation of AKT at
T308 can be PI3K independent, while S473 phosphorylation is
still PI3K dependent [29,30,31]. The stress-induced AKT
activation may result from enhanced PDK1::AKT interaction
independent of PtdInsP3 and membrane localization. PI3K-
independent AKT activation may play an important role in
promoting cancer cell survival since cancer cells usually exist in
stressed physiological conditions lacking sufficient growth factors,
nutrients, or oxygen.
Recently, AKT has been shown to form a complex with PDK1
in resting cells but the intramolecular interaction between AKT
PH domain and kinase domain prevents the phosphorylation by
PDK1. PtdInsP3 binding induces a conformational change
enabling T308 phosphorylation (Calleja, 2007). The PDK1-
IFPC::IFPN-AKT1 complex in our study represents a potent
association between AKT1 and PDK1 which is sufficient for T308
phosphorylation on AKT1. Thus we postulate that, besides
PtdInsP3, other molecules could also induce functional associa-
tions between PDK1 and AKT. Our results suggest that direct
targeting of the PDK1::AKT interaction is a possible strategy for
cancer drug development.
In summary, we have employed PCA as a novel tool to
characterize AKT1 phosphorylation by PDK1 and provided
direct evidence showing stabilized AKT1 association with PDK1
by the reconstituted IFP is sufficient for AKT1 phosphorylation
by PDK1 independent of PI3K and membrane localization.
PtdInsP3 binding and membrane localization are not prerequi-
sites for phosphorylation of T308 in AKT by PDK1, but rather
appear to function to induce association of PDK1 and AKT in a
conformation that allows AKT phosphorylation. The reconsti-
tuted IFP functions to associate AKT1 and PDK1, similar to the
function of PtdInsP3 in normal cells. The complex generated in
the study proved to be useful to test different inhibitors and
dissect specific functions including off target effects of drugs. The
same procedure could be used to characterize other protein
complexes.
Materials and Methods
Cell culture and plasmids
HeLa cell line used in the study is a Tet-on derivative from BD
Clontech (Palo Alto, CA). U2OS was from ATCC (Manassas,
VA). Cells were cultured in Dulbecco’s modified Eagle’s medium
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf
serum. Plasmids 11117-Y101 (expressing IFPN-AKT1) and
21622-Y108 (expressing PDK1-IFPC) were from Odyssey Thera.
Inc. (San Ramon, CA) [15]. A plasmid expressing PDK1-GFP was
constructed by replacing the IFPC fragment on 21622-Y108 with
full length GFP. Plasmids expressing the two PH domain mutants,
IFPN-AKT1(R25A) and PDK1(R474A)-IFPC, were constructed
by mutagenesis from 11117-Y101 and 21622-Y108 with Quik-
change mutagenesis kit (Stratagene, La Jolla, CA) and confirma-
tion by sequencing. Construction of IFPC-ACTN4D310-911 was
described earlier[12]. The cells were transfected using FuGENE 6
transfection reagent (Roche, Indianapolis, IN) following the
manufacturer’s protocol.
Reagents and antibodies
LY294002 was from CalBiochem (San Diego, CA). PI103 was
synthesized at M. D. Anderson Cancer Center according to the
structure reported [24]. GDC0941 was from Axon (Groningen,
The Netherlands). TGX286 was from GSK (Research Triangle
Park, NC). AKT1/2 PH domain inhibitor, Akti-1/2, (1,3-dihydro-
1-(1-((4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl)methyl)-
4-piperidinyl)-2H-benzimidazol-2-one) was synthesized (Patent
Number WO2003086404) by Keith Woods at Abbott Laborato-
ries (Abbott Park, IL). Rapamycin was from Cell Signaling
Technology, Inc. (Beverly, MA). Paclitaxel was from Bristol-Myers
Squibb (Princeton, NJ). Leptomycin B (LMB) was from Sigma
(St. Louis, MO). Goat AKT1 antibody and mouse PDK1 antibody
for Co-IP, normal serum, protein A/G agarose, anti-total GSK3,
and b-actin antibody were from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Western blotting antibodies for total AKT,
phospho-AKT, phospho-AKT substrates, phospho-GSK3, phos-
pho-S6, total PDK1, and Rictor were from Cell Signaling
Technology, Inc.
RNAi, co-immunoprecipitation (Co-IP), and western
blotting
Four siRNAs targeting human Rictor and a non-targeting
siRNA pool were from Dharmacon (Lafayette, CO). RNAi
silencing was performed according to manufacturer’s protocol.
To prepare cell lysates for western blotting, cells were lysed in
RIPA buffer (Tris-HCl, pH 7.4, 50 mM; NaCl, 150 mM; NP-40,
1%; Sodium deoxycholate, 0.5%; SDS, 0.1%) supplemented with
protease inhibitor and phosphatase inhibitor cocktail (Pierce,
Rockford, IL). To prepare cell lysates for Co-IP, cells were lysed in
NP40 buffer (Tris-HCl, pH 8.0, 50 mM; NaCl, 150 mM; NP-40,
1%) with protease inhibitor cocktail. Co-IP and western blotting
were performed as previously described [32].
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Cells were plated into 96-well plates at 3000 cells/well and
incubated for 18–24 hours then treated with drugs for 24 hours.
Cell viability was determined by CellTiter Blue Cell Viability assay
(Promega, Madison, WI) according to manufacturer’s protocol.
Supporting Information
Figure S1 IFPN-AKT1 phosphorylation on S473 in the
complex is mTORC2 dependent. HeLa cells stably co-expressing
the PDK1-IFPC::IFPN-AKT1 complex were transfected with
Rictor siRNA or a non-targeting siRNA (NT-siRNA) pool.
Twenty-four hours post-transfection, cells were serum starved for
overnight and then treated with LY294002 (20 mM) for 3 hours.
Parental HeLa cells transfected with Rictor siRNA or non-
targeting siRNA were included as controls (cultured in complete
medium). The arrow head designates IFPN-AKT1. The arrow
designates endogenous AKT. siRNA-mediated Rictor depletion
led to a substantial reduction in IFPN-AKT1 S473 phosphoryla-
tion, while T308 phosphorylation was not affected, indicating that
S473 phosphorylation was dependent on mTORC2 activity in the
complex. GSK3 was comparably phosphorylated with or without
Rictor knockdown, suggesting that IFPN-AKT1 phosphorylated at
T308 retained the ability to phosphorylate GSK3 despite a
substantial decrease in S473 phosphorylation. Multiple indepen-
dent Rictor siRNA were used with similar results (data not shown).
Found at: doi:10.1371/journal.pone.0009910.s001 (0.60 MB
TIF)
Figure S2 PDK1 overexpression alone is not sufficient for the
phosphorylation of GSK3. Four cell lines, parental HeLa, cells
stably expressing IFPN-AKT1 only, cells stably co-expressing
IFPN-AKT1 and PDK1-IFPC, and cells stably expressing PDK1-
GFP alone were serum starved for overnight then treated with
LY294002 (20 mM) for 3 hours. The arrow head designates IFPN-
AKT1. The arrow designates endogenous AKT. Phosphorylation
of GSK3 was blocked by LY294002 in cells overexpressing PDK1-
GFP alone, indicating that PDK1 overexpression was not
sufficient for the observed PI3K-independent phosphorylation of
AKT substrates.
Found at: doi:10.1371/journal.pone.0009910.s002 (0.41 MB
TIF)
Figure S3 Comparison of HeLa cell AKT and PDK1 levels with
other cancer cell lines. Quantitative Reverse Phase Protein Arrays
(RPPA) was performed at the CCSG RPPA core facility at MD
Anderson Cancer Center to determine relative levels of AKT and
PDK1 in different cell lines. The cell lines, including
MCF7(Breast), T47D(Breast), UACC62(Melanoma), M14(Mela-
noma), MALME(Melanoma), WM3451(Melanoma), HOP-
62(Lung), COLO205(Colon), HCC2998(Colon), and K562(Leu-
kemia), were shown for relative AKT or PDK1 level comparing
with HeLa. Higher levels of AKT (2–4 fold of HeLa AKT) and
PDK1 (5–6 fold of HeLa PDK1) were frequently seen in other
cancer cell lines.
Found at: doi:10.1371/journal.pone.0009910.s003 (0.13 MB TIF)
Figure S4 AKT phosphorylation and activation in the PDK1-
IFPC::IFPN-AKT1 complex with GDC0941 treatment. Four cell
lines, parental HeLa, cells stably expressing IFPN-AKT1 only, co-
expressing IFPN-AKT1 and PDK1-IFPC, and co-expressing
IFPN-AKT1 and IFPC-ACTN4, were serum starved for overnight
then treated or not treated with GDC0941 (10 mM) for 3 hours.
Cells were lysed in RIPA buffer supplied with protease inhibitors
and phosphatase inhibitors. Lysates (50 mg/lane) were resolved in
10% SDS PAGE. Antibodies for each blot were listed to the left of
the blots. Beta-actin immunoblotting shows equivalent loading.
The arrow head designates IFPN-AKT1. The arrow designates
endogenous AKT. Scanning densitometric values of western blots
were obtained using the NIH image 1.63.1 software. IFPN-AKT1
phosphorylation was normalized to total IFPN-AKT1.
GSK3(S21/9) phosphorylation was normalized to total GSK3.
S6(S235/236) phosphorylation was normalized to beta-actin. Data
were presented as relative conversion to values of the sample in
lane 7.
Found at: doi:10.1371/journal.pone.0009910.s004 (1.23 MB TIF)
Figure S5 AKT phosphorylation and activation in the PDK1-
IFPC::IFPN-AKT1 complex with Akti-1/2 treatment. The
experiments was performed and the data were processed the
same as above in Figure S3 except for the cells were treated with
Akti-1/2 at 5 mM.
Found at: doi:10.1371/journal.pone.0009910.s005 (1.28 MB TIF)
Figure S6 The effects of the PDK1-IFPC::IFPN-AKT1 complex
on cell viability. Three cell lines were used in cell viability assays
including parental HeLa and two stable HeLa cell lines expressing
IFPN-AKT1 alone or co-expressing IFPN-AKT1 and PDK1-
IFPC. Cells were plated in 96-well plates in complete medium at
3000 cells/well. After 18–24 hours, cells were treated with drugs at
different concentrations for 24 hours. Cell viability was measured
by CellTiter Blue Cell Viability assay according to manufacturer’s
instructions. Data presented as survival rates normalized to non-
treatment controls, respectively. Error bars were the standard
deviations of triplicates of each treatment. (A) The PDK1-
IFPC::IFPN-AKT1 complex has no effect on cell viability with
Rapamycin treatment. (B) The PDK1-IFPC::IFPN-AKT1 com-
plex promotes cell viability with paclitaxel treatment.
Found at: doi:10.1371/journal.pone.0009910.s006 (1.45 MB TIF)
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